Search results
Results From The WOW.Com Content Network
Thrombocytopenia can be contrasted with the conditions associated with an abnormally high level of platelets in the blood – thrombocythemia (when the cause is unknown), and thrombocytosis (when the cause is known).
Hetrombopag (also known as rafutrombopag; trade name Hengqu) is a pharmaceutical drug for the treatment of thrombocytopenia and anemia. [1] [2] [3]It is a non-peptide small‐molecule thrombopoietin receptor agonist.
Aplastic anemia causes a deficiency of all blood cell types: red blood cells, white blood cells, and platelets. [5] [6] It occurs most frequently in people in their teens and twenties but is also common among the elderly. It can be caused by immune disease, or by exposure to chemicals, drugs, or radiation. However, in about half of cases, the ...
Drug-independent autoantibodies are found in Drug-induced autoimmune hemolytic anemia because of beta-lactamase inhibitors and platinum-based chemotherapeutics. These autoantibodies can sometimes bind and react to red blood cells even in the absence of whatever drug triggered the anemia .
Thrombotic thrombocytopenic purpura (TTP) initially presents with a range of symptoms that may include severe thrombocytopenia (platelet count usually < 30,000/mm³), microangiopathic hemolytic anemia (evidenced by schistocytes in the blood smear), and various clinical signs such as petechiae, purpura, neurologic symptoms, myocardial ischemia ...
The 4T score for heparin-induced thrombocytopenia [9] [10] Thrombocytopenia 2 points if the fall in platelet count is >50% of the previous value, AND the lowest count (nadir) is 20–100 × 10 9 /liter 1 point if the fall is 30–50% or the nadir is 10–19 × 10 9 /liter No points if the fall is less than 30% or the nadir is <10 × 10 9 /liter ...
Eltrombopag, sold under the brand name Promacta among others, is a medication used to treat thrombocytopenia (abnormally low platelet counts) and severe aplastic anemia. [3] [4] Eltrombopag is sold under the brand name Revolade outside the US and is marketed by Novartis. [6] It is a thrombopoietin receptor agonist. [3] It is taken by mouth. [3] [4]
Thrombotic microangiopathy (TMA) is a pathology that results in thrombosis in capillaries and arterioles, due to an endothelial injury. [1] It may be seen in association with thrombocytopenia, anemia, purpura and kidney failure.